Sustanon ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
113筋ジストロフィー2

113. 筋ジストロフィー


臨床試験数 : 646 薬物数 : 471 - (DrugBank : 105) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 170
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2015-003195-68-GB
(EUCTR)
11/11/201526/10/2015Testosterone therapy in DMDObservational study of clinical outcomes for testosterone treatment of pubertal delay in Duchenne Muscular Dystrophy. - Testosterone therapy in Duchenne Muscular Dystrophy Duchenne Muscular Dystrophy
MedDRA version: 18.1;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Sustanon 250
Product Name: Sustanon 250
Product Code: PRD2175434
INN or Proposed INN: testosterone propionate
INN or Proposed INN: testosterone phenylpropionate
INN or Proposed INN: testosterone isocaproate
INN or Proposed INN: testosterone decanoate
The Newcastle upon Tyne NHS Hospitals Foundation TrustNULLNot RecruitingFemale: no
Male: yes
20Phase 3United Kingdom
2NCT02571205
(ClinicalTrials.gov)
November 201524/8/2015Testosterone Therapy for Pubertal Delay in Duchenne Muscular DystrophyObservational Study of Clinical Outcomes for Testosterone Treatment of Pubertal Delay in Duchenne Muscular DystrophyDuchenne Muscular DystrophyDrug: Sustanon (testosterone)Newcastle-upon-Tyne Hospitals NHS TrustNULLCompleted12 Years17 YearsMale15United Kingdom